CoreWeave Stock Sinks on AI Debt Despite Revenue Surge
CoreWeave shares have fallen more than a third in October as investors worry about roughly $52 billion in AI data-center debt, even as revenue more than…
A Tokyo-listed Brazil ETF fell nearly 15% in Asian trade after Lula's runoff win. Goldman Sachs outlined an extreme repricing scenario.
Trading in Tokyo offers only an early, low-liquidity read, so the true reckoning arrives once Brazil's own market opens; the real, local rates curve and the Bovespa are likely to take the biggest hit in any repricing. Goldman Sachs' figures describe a worst-case scenario rather than a baseline one, yet they show how large the move could be, with the currency and the far end of the yield curve most exposed. Positioning also plays a part: after the first round, markets rose because investors anticipated a different result, so some of the selling may reflect an unwinding of that trade rather than a new assessment of policy. A disorderly selloff could spill into other Latin American currencies and broader emerging-market sentiment, while a contained reaction might quickly draw in buyers looking for bargains.
---
The second-round comeback was rare, and the market's early verdict came as a near 15% drop in a Tokyo-listed Brazil ETF, suggesting investors had prepared for a different outcome.
At a glance:
After Luiz Inacio Lula da Silva won Sunday's runoff, Brazilian assets are in line for a sharp repricing; the first Asian trading signals indicate heavy selling when domestic trading begins.
Lula was the winner over right-wing Senator Flavio Bolsonaro with about 52% to 48% and a margin of more than 4 million votes once nearly all ballots were counted; that gave him a fourth non-consecutive term. It also represented a comeback, since Lula had been behind in the first round held on October 4; he is now the first candidate since 1989 to lose that round and still win the presidency.
The first market reaction was severe. Reuters reported that a Tokyo-listed exchange-traded fund tracking the Bovespa index dropped nearly 15% in Asian trade after the win was announced. Liquidity in these offshore products can be limited, but the slide still gives an early sense of how investors might treat Brazilian assets.
Goldman Sachs described on Monday how an extreme case could play out. In that scenario, the dollar could gain as much as 10% against the real, long-dated government bond yields could climb about 200 basis points, credit spreads could widen 30 to 40 basis points, and Brazilian equities could drop around 15%, Goldman said. The bank made clear this was a tail scenario rather than the expected path, but the numbers still emphasize how much repricing is at stake.
Some of the selling stems from positioning. With Bolsonaro leading after round one, investors bid Brazilian markets higher on the greater likelihood of his win. The runoff outcome now breaks that expectation, exposing those positions.
Focus shifts to the open of Brazilian trading, where the real, local interest-rate futures and the Bovespa will reveal if selling proves as heavy as in Tokyo or more restrained. Early indications from Lula's team on economic and fiscal policy for his new term are also being watched, since they could help decide whether the initial drop deepens or begins to settle.
Share to
Disclaimer: this article comes from third-party media and is provided for reference only. It does not constitute investment advice. Crypto and other financial products carry significant price volatility risk, so please make your own decisions carefully.
CoreWeave shares have fallen more than a third in October as investors worry about roughly $52 billion in AI data-center debt, even as revenue more than…
Asia-Pacific stocks mostly fell; a Tokyo-listed Bovespa ETF slumped nearly 15% after Lula's win, while oil eased and gold hovered near a three-month low.
Meta shares fell 7% as AI spending exceeded cash flow; other Big Tech earnings may face same investor scrutiny.
German researchers made cells from an 80-year-old appear decades younger in the lab. A separate eye therapy has already produced early human trial data.